Study of Rubitecan in Cancer Patients With Renal or Hepatic Dysfunction

Inclusion Criteria: * The patient is at least 18 years of age. * The patient has histologically or cytologically proven malignancy recurrent or refractory to standard treatment or for which there is no standard therapy. * The patient has measurable disease. * The patient has sufficiently recovered from the acute toxic effects of previous chemotherapy, radiotherapy (no less than 3 weeks prior to randomization), and/or immunotherapy. * The patient's estimated life expectancy is at least 8 weeks. * The patient has a National Cancer Institute Common Toxicity Criteria (NCI CTC) Performance Status between 0 and 2. * The patient has adequate bone marrow function. * The patient must not have active central nervous system (CNS) metastases. Exclusion Criteria: * The patient has any serious, uncontrolled intercurrent illness or infection. * The patient is receiving anti-retroviral therapy (HAART) for HIV infection. * The patient is pregnant or nursing.